Contact
searchSearch
HMP Global

News

News
Balancing Clinical Outcomes and Cost: The Value of Biosimilars in Retinal Disease Management
09/26/2025
Juliet Gallagher
A recent study examining the impact of retinal diseases highlights their significant clinical, social, and economic burden.
A recent study examining the impact of retinal diseases highlights their significant clinical, social, and economic burden.
A recent study examining the...
09/26/2025
First Report Managed Care
News
Trump Administration to Test AI-Powered Prior Authorization in Medicare
09/25/2025
Grace Taylor, MS, MA
The Trump administration is set to launch a decade-long Medicare pilot that uses artificial intelligence (AI)-driven prior authorization to curb costs, sparking bipartisan concern over access to care and patient safety.
The Trump administration is set to launch a decade-long Medicare pilot that uses artificial intelligence (AI)-driven prior authorization to curb costs, sparking bipartisan concern over access to care and patient safety.
The Trump administration is set...
09/25/2025
First Report Managed Care
News
Policy Impact: FDA’s Interchangeability Designation Expands Biosimilar Access
09/25/2025
Juliet Gallagher
Insulin glargine, marketed as Semglee and its biosimilar insulin glargine-yfgn, was granted interchangeable status, allowing pharmacists to substitute it for the branded originator without requiring prescriber intervention. A new economic...
Insulin glargine, marketed as Semglee and its biosimilar insulin glargine-yfgn, was granted interchangeable status, allowing pharmacists to substitute it for the branded originator without requiring prescriber intervention. A new economic...
Insulin glargine, marketed as...
09/25/2025
First Report Managed Care
News
How Timing Shapes Biosimilar Success: Insights from US Market Data
09/24/2025
Juliet Gallagher
A recent study published in Value in Health sheds light on the competitive dynamics of biosimilar drugs in the US, specifically examining whether first-mover advantages resemble those seen in generic drug markets.
A recent study published in Value in Health sheds light on the competitive dynamics of biosimilar drugs in the US, specifically examining whether first-mover advantages resemble those seen in generic drug markets.
A recent study published in...
09/24/2025
First Report Managed Care
Hero Image
News
‘First Report Managed Care’ Webinar to Address Specialty Pharmacy Disruption, Cost Pressures, and Patient Access
09/24/2025
Danielle Sposato
Rising specialty drug costs, surging demand for GLP-1 therapies, and ongoing supply chain and policy challenges are putting patient access at risk. To address these pressures, First Report Managed Care will host a complimentary 60-minute...
Rising specialty drug costs, surging demand for GLP-1 therapies, and ongoing supply chain and policy challenges are putting patient access at risk. To address these pressures, First Report Managed Care will host a complimentary 60-minute...
Rising specialty drug costs,...
09/24/2025
First Report Managed Care
News
Biosimilars Match Humira in Structure, Show Greater Stability Under Real-World Stress
09/22/2025
Juliet Gallagher
A new analytical study underscores how advanced nuclear magnetic resonance (NMR) spectroscopy can sharpen head-to-head comparisons between Humira (adalimumab) and its biosimilars—particularly when products are challenged under real-world...
A new analytical study underscores how advanced nuclear magnetic resonance (NMR) spectroscopy can sharpen head-to-head comparisons between Humira (adalimumab) and its biosimilars—particularly when products are challenged under real-world...
A new analytical study...
09/22/2025
First Report Managed Care
News
$3.2 Million Saved Through Biosimilar Substitution in Rheumatology Clinics
09/19/2025
Juliet Gallagher
A study published in the Journal of Clinical Rheumatology found that a recent initiative at a large academic medical center significantly increased biosimilar uptake and generated substantial cost savings through targeted interventions.
A study published in the Journal of Clinical Rheumatology found that a recent initiative at a large academic medical center significantly increased biosimilar uptake and generated substantial cost savings through targeted interventions.
A study published in the Journal...
09/19/2025
First Report Managed Care
News
Pharmacists Lead, Physicians Lag? Provider Perspectives on Biosimilars and Interchangeability
09/18/2025
Juliet Gallagher
A new cross-sectional survey of 249 US outpatient clinicians—150 physicians and 99 pharmacists who treat immunologic conditions—offers a timely snapshot of how front-line decision-makers view biosimilars and the US Food and Drug...
A new cross-sectional survey of 249 US outpatient clinicians—150 physicians and 99 pharmacists who treat immunologic conditions—offers a timely snapshot of how front-line decision-makers view biosimilars and the US Food and Drug...
A new cross-sectional survey of...
09/18/2025
First Report Managed Care
News
Payer-Driven Biosimilar Preferences Create Financial and Operational Strain for Health Systems
09/17/2025
Juliet Gallagher
The expansion of US Food and Drug Administration (FDA)-approved biosimilars has been heralded as a major advancement for lowering healthcare costs in the US, with the potential to reduce both system-wide expenditures and patient out-of-pocket...
The expansion of US Food and Drug Administration (FDA)-approved biosimilars has been heralded as a major advancement for lowering healthcare costs in the US, with the potential to reduce both system-wide expenditures and patient out-of-pocket...
The expansion of US Food and...
09/17/2025
First Report Managed Care
News
DTX101 Gene Therapy Ends Development, Offers Key Lessons for Future Hemophilia B Treatment Strategies
09/16/2025
Grace Taylor, MS, MA
Early-phase trials of the DTX101 gene therapy in hemophilia B showed manageable safety but insufficient efficacy, leading to program discontinuation while offering critical insights for future gene therapy development.
Early-phase trials of the DTX101 gene therapy in hemophilia B showed manageable safety but insufficient efficacy, leading to program discontinuation while offering critical insights for future gene therapy development.
Early-phase trials of the DTX101...
09/16/2025
First Report Managed Care

Behind the Bill

Behind the Bill
The Senate’s $3 Trillion Deal. Tax Relief Now, Medicaid Coverage Loss Later?
07/02/2025
Katie Hayes, MJ
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After...
07/02/2025
First Report Managed Care
Behind the Bill
When a Cap Isn’t Just a Cap: How a Provider Tax Proposal Could Reshape Medicaid Financing
06/25/2025
Katie Hayes, MJ
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most...
06/25/2025
First Report Managed Care
Behind the Bill
Rewriting the Safety Net? Inside the Senate’s Changes to Medicaid and the ACA
06/18/2025
Katie Hayes, MJ
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve...
06/18/2025
First Report Managed Care
Behind the Bill
How States Might Respond to the One Big Beautiful Bill Act
06/11/2025
Katie Hayes, MJ
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill...
06/11/2025
First Report Managed Care
Behind the Bill
Is the Affordable Care Act on the Chopping Block? What the One Big Beautiful Bill Act Tells Us.
06/04/2025
Katie Hayes, MJ
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of...
06/04/2025
First Report Managed Care
Behind the Bill
From House to Senate: The Journey of Cutting Medicaid
05/28/2025
Katie Hayes, MJ
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of...
05/28/2025
First Report Managed Care
Behind the Bill
Eligibility, Paperwork, and Penalties: The Not-So-Hidden Costs of Medicaid ‘Reform’
05/21/2025
Katie Hayes, MJ
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week...
05/21/2025
First Report Managed Care
Behind the Bill
A Busy Week in Drug Pricing Policy: Aligning US Drug Prices With Global Standards?
05/14/2025
Katie Hayes, MJ
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for...
05/14/2025
First Report Managed Care
BEHIND THE BILL
When Agencies Lose Power: How 3 Seismic Shifts are Transforming Pharmaceutical Regulation
05/07/2025
Katie Hayes, MJ
In the span of just 9 months, the landscape of administrative law has undergone a transformation so profound that pharmaceutical executives, health care providers, and patients alike are struggling to navigate the new terrain. The Supreme...
In the span of just 9 months, the landscape of administrative law has undergone a transformation so profound that pharmaceutical executives, health care providers, and patients alike are struggling to navigate the new terrain. The Supreme...
In the span of just 9 months,...
05/07/2025
First Report Managed Care
Behind the Bill
The Medicare Paradox, Part 3: Strategic Trade Doesn’t Have to be a Zero-Sum Game
05/07/2025
Katie Hayes, MJ
Over the past 2 weeks, I’ve examined the growing friction between the Section 232 pharmaceutical tariff investigations and the Medicare drug pricing reforms authorized by the Inflation Reduction Act (IRA). These 2 policy agendas—industrial...
Over the past 2 weeks, I’ve examined the growing friction between the Section 232 pharmaceutical tariff investigations and the Medicare drug pricing reforms authorized by the Inflation Reduction Act (IRA). These 2 policy agendas—industrial...
Over the past 2 weeks, I’ve...
05/07/2025
First Report Managed Care

Subscribe and Stay Ahead With Daily Industry Insights

First Report Managed Care Newsletter

Trending Articles

News
Updated AS and NrxSpA Treatment Recommendations Identify Common Diagnosis Issues, Solutions
10/06/2023
Hannah Musick
Updated evidence-based recommendations were released for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis, including the use of biologics and the role of imaging in patient management.
Updated evidence-based recommendations were released for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis, including the use of biologics and the role of imaging in patient management.
Updated evidence-based...
10/06/2023
First Report Managed Care
John Hennessy Headshot
Videos
Biosimilars, Explained
10/24/2023
John Hennessy, MBA
In this video, John Hennessey, MBA, Valuate Health Consultancy, explains biosimilars in relation to cancer care: what they are, why they matter, and how they have and haven’t lived up to their promise.
In this video, John Hennessey, MBA, Valuate Health Consultancy, explains biosimilars in relation to cancer care: what they are, why they matter, and how they have and haven’t lived up to their promise.
In this video, John Hennessey,...
10/24/2023
First Report Managed Care
News
The Toxic Effects of Tea Tree Oil for Treatment of Demodex Mites
11/16/2023
Hannah Musick
“Our findings show that T4O causes a dose- and time-dependent decrease in cell survival of immortalized human meibomian gland epithelial cells,” said researchers.
“Our findings show that T4O causes a dose- and time-dependent decrease in cell survival of immortalized human meibomian gland epithelial cells,” said researchers.
“Our findings show that T4O...
11/16/2023
First Report Managed Care
News
Comfort, Interest, and Therapy Choices Differ Between Hidradenitis Suppurativa Experts and Non-Experts in Complex Cases
12/20/2023
Lisa Kuhns, PhD, MD
“Although North American guidelines for HS management were recently published in 2019 from both the United States and Canadian HS Foundations, barriers to HS expertise among dermatologists still exist,” wrote coauthors.
“Although North American guidelines for HS management were recently published in 2019 from both the United States and Canadian HS Foundations, barriers to HS expertise among dermatologists still exist,” wrote coauthors.
“Although North American...
12/20/2023
First Report Managed Care
News
What Do the Drug Price Changes Announced in January Tell Us?
02/14/2024
Dean Celia
The initial findings regarding the changes in prescription drug prices for 2024 have arrived. In this summary, we’ll outline shifts and seek insights from Edmund J Pezalla, MD, founder and CEO, Enlightenment Bioconsult, examine underlying...
The initial findings regarding the changes in prescription drug prices for 2024 have arrived. In this summary, we’ll outline shifts and seek insights from Edmund J Pezalla, MD, founder and CEO, Enlightenment Bioconsult, examine underlying...
The initial findings regarding...
02/14/2024
First Report Managed Care

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use